D-Ala.sup.5 -somatostatin and intermediates thereto
AssigneeEli Lilly and Company
InventorJames E. Shields
Life of this patent
Estimating the term…
Abstract
The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically acceptable acid addition salts inhibit the secretion of gastric acid.
Claims9
A compound of the formula ##STR9## and its pharmaceutically acceptable non-toxic acid addition salts, and intermediates to said compound, said intermediates having the formula R-L-Ala-Gly-L-Cys(R.sub.1)-L-Lys(R.sub.2)-D-Ala-L-Phe-L-Phe-L-Trp(R.sub.5) -L-Lys(R.sub.2)-L-Thr(R.sub.3)-L-Phe-L-Thr(R.sub.3)-L-Ser(R.sub.4)-L-Cys(R. sub.1)-X;
- in which
- R is hydrogen or an .alpha.-amino protecting group;
- R.sub.1 is hydrogen or a thio protecting group;
- R.sub.2 is hydrogen or an .epsilon.-amino protecting group;
- R.sub.3 and R.sub.4 each are hydrogen or a hydroxy protecting group;
- R.sub.5 is hydrogen or formyl;
- and
- X is hydroxy or ##STR10## in which the resin is polystyrene;
- with the proviso that, when X is hydroxy, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 each are hydrogen, and, when X is ##STR11## R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each are other than hydrogen.
Dependencies are inferred from the claim text.